(Press-News.org) BOSTON, June 1, 2025 – Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
These results stem from the ATOMIC trial, a phase 3 multicenter, randomized, open-label study of patients with surgically resected stage 3 dMMR colon cancer. The trial is sponsored by the National Cancer Institute (NCI) and led by the NCI-funded Alliance for Clinical Trials in Oncology, part of the National Clinical Trials Network (NCTN). Dr. Frank Sinicrope of Mayo Clinic was the overall study chair and will present the findings today in the ASCO Plenary Session.
“We know from previous clinical trials that an immune checkpoint inhibitor is beneficial to patients with metastatic dMMR colon and rectal cancer, but it was unclear whether there would be a benefit in the adjuvant setting following surgery,” said Meyerhardt, senior author of the study and co-chair of the Alliance Gastrointestinal Committee. Meyerhardt is also the chief clinical research officer and co-director of the Colon and Rectal Cancer Center at Dana-Farber. “Now, through this NCI-funded trial, we’ve shown that the immune checkpoint inhibitor atezolizumab, when combined with standard chemotherapy, can help reduce the risk of recurrence by 50% in patients with dMMR colon cancer after surgery.”
Patients with the dMMR subtype of colon cancer (also referred to as MSI or MSI-high) carry tumors with a molecular characteristic known as microsatellite instability. This feature is often used as a biomarker to help predict which patients are likely to respond to immune checkpoint inhibitors, such as atezolizumab.
To test whether patients with stage 3 colon cancer would benefit from the addition of this drug, which is an anti-PD-L1 monoclonal antibody, investigators launched the ATOMIC trial. The study randomized patients with resected stage 3 colon cancer into two treatment groups: standard adjuvant chemotherapy (consisting of 5-fluorouracil, leucovorin, and oxaliplatin; abbreviated FOLFOX), and FOLFOX combined with atezolizumab. The primary endpoint of the study was disease-free survival; secondary endpoints were overall survival and adverse event profile.
From September 2017 to January 2023, a total of 712 patients (including one pediatric patient) were enrolled. The median age was 64 and over half of patients (55.1%) were female.
Results from the ATOMIC trial reveal that the three-year disease-free survival was 86.4% (95% confidence interval, 81.8 to 89.9) in the atezolizumab group and 76.6% (95% confidence interval, 71.3 to 81.0) in the FOLFOX alone group. This represents a statistically significant improvement in disease-free survival — reducing the risk of recurrence or death by 50% for patients treated with atezolizumab in combination with chemotherapy, compared to those receiving chemotherapy alone.
Colorectal cancer is a leading cause of cancer-related deaths in the United States and around the world. In addition, the rates of the disease among young adults (those under 50) have been on the rise for the last two decades — increasing by roughly 2.4% per year. And more young people are dying because their cancers are typically diagnosed at a more advanced stage. Until now, the only treatment for patients with stage 3 colon cancer has been standard adjuvant chemotherapy drugs, like the FOLFOX regimen.
“The results of the ATOMIC trial are extremely compelling and demonstrate a substantial benefit to patients,” said Meyerhardt. “Not only do they provide the evidence for a new standard of care in this subgroup of patients with colon cancer, but they also illustrate the power of the National Clinical Trials Network and federal funding from the NCI to test clinical hypotheses and ultimately improve the lives of cancer patients.”
In addition to sponsorship by the NCI, the ATOMIC trial is also conducted in partnership with Genentech, a member of the Roche Group, through a Cooperative Research and Development Agreement (CRADA). The trial was also open in partnership with the German group Arbeitsgemeinschaft Internistische Onkologie (AIO). To learn more about the ATOMIC trial, visit ClinicalTrials.gov.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
###
END
BOSTON, June 1, 2025 – Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival.
“One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” says first author Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber ...
A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.
The SERENA-6 study, published June 1 in the New England Journal of Medicine and presented concurrently at the annual meeting of the American Society for Clinical Oncology, was conducted at multiple medical centers, principally in Europe, East Asia and the United States, including at Weill ...
June 1, 2025 — The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically ...
Late-breaking abstract featured at ASCO 2025
ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific ...
By leveraging the structural parallels between genomic sequences and natural language, these AI-driven models can decode complex genetic information, offering unprecedented insights into plant biology. This advancement holds promise for accelerating crop improvement, enhancing biodiversity conservation, and bolstering food security in the face of global challenges.
Traditionally, plant genomics has grappled with the intricacies of vast and complex datasets, often limited by the specificity of traditional machine learning models and the scarcity of annotated ...
This research provides key insights into how microbial inoculants can offer a cost-effective, eco-friendly strategy to enhance crop resilience in saline soils.
Soil salinization is a major global challenge that severely impacts agricultural productivity, with over 3% of the Earth’s terrestrial surface affected. It threatens food security by causing osmotic, ionic, and oxidative stress, which can reduce crop yields by more than 50%. Traditional remediation methods, such as physical and chemical interventions, are often prohibitively expensive. However, ...
While moms have traditionally gotten much of the focus when it comes to children’s eating habits, a new study highlights the importance of dads in shaping a child’s relationship with food. According to the study, young children were more likely to consume the recommended amount of fruits and vegetables if their father ate a healthier diet during his teen years.
The study is based on data from 669 men who answered questionnaires about their eating habits during adolescence and then, years later, provided information about their attitudes and behaviors surrounding their children’s diet.
“Our ...
May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.
“These results show that combining immune checkpoint inhibition targeting the PD-1: PD-L1 pathway ...
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.
“It is both an honor and humbling to develop clinical trials ...
Merremia boisiana, a member of the Convolvulaceae family, a fast-growing vine native to tropical rainforests and known for its vibrant golden flowers and astonishing climbing ability, grows at speeds exceeding 12 cm per day, often overwhelming native vegetation and disrupting forest ecosystems. Despite its ecological importance and genetic proximity to economically vital crops like sweet potato (Ipomoea batatas), little was known about its genomic makeup until now.
A study (DOI:10.48130/tp-0025-0007) published in Tropical Plants on 24 March 2025 by Fei Chen and Wenquan Wang’s team, Hainan University, marks a significant leap ...
